Abstract

BackgroundYakuchinone A has a plethora of beneficial biological effects. However, the pharmacokinetic (PK) data of yakuchinone A still remain unknown so far. Furthermore, the quantification of yakuchinone A in biological samples has not been reported in the literature. Therefore, in the present study we aimed to develop a new method for the fast, efficient and accurate assessment of yakuchinone A concentration in plasma, as a means for facilitating the PK evaluation of yakuchinone A.ResultsA liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) method was developed and validated for the determination of yakuchinone A in rat plasma. Mass spectrometric and chromatographic conditions were optimized. Plasma samples were pretreated by protein precipitation with methanol. LC separation was performed on a Phenomenex Luna C18 column with gradient elution using a mobile phase consisting of methanol–water containing 0.5 mM formic acid (HCOOH) at a flow rate of 0.28 mL/min. ESI-MS spectra were acquired in positive ion multiple reaction monitoring mode (MRM). The precursor-to-product ion pairs used for MRM of yakuchinone A and yakuchinone B were m/z 313.1 → 137.0 and 311.2 → 117.1, respectively. Low concentration of HCOOH reduced the ion suppression caused by matrix components and clearly improved the analytical sensitivity. Yakuchinone A showed good linearity over a wide concentration range (r > 0.99). The accuracy, precision, stability and linearity were found to be within the acceptable criteria. This new method was successfully applied to analyze the rat plasma concentration of parent yakuchinone A after a single oral administration of SuoQuan capsules. Low systemic exposure to parent yakuchinone A was observed.ConclusionThe proposed method is sensitive and reliable. It is hoped that this new method will prove useful for the future PK studies.

Highlights

  • Yakuchinone A has a plethora of beneficial biological effects

  • We report the development and full validation of a rapid and sensitive method based on high performance liquid chromatography with tandem mass spectrometry (LC-MS/MS) for determination of yakuchinone A in rat plasma, as well as the use of this method to analyze samples obtained during a single oral PK study in Sprague-Dawley (SD) rats

  • We found that plasma parent yakuchinone A observed only up to 0.5 h after dosing and the concentrations were quite low with the mean Cmax at 4.62 ng/mL

Read more

Summary

Introduction

Yakuchinone A has a plethora of beneficial biological effects. the pharmacokinetic (PK) data of yakuchinone A still remain unknown so far. In East Asian traditional medicine, these edible fruits are widely used for treating dyspepsia, diarrhea, polyuria, and gastralgia [2]. Pharmacological studies both in vitro and in vivo have confirmed that yakuchinone A has a plethora of beneficial biological effects. Yakuchinone A inhibits the expression of cyclooxygenase-2 and of inducible nitric oxide synthase, as well as the expression of tumor necrosis factor-alpha mRNA in mouse skin [5,8]. These findings demonstrate that this compound has anti-inflammatory properties. In our lab, we have found that yakuchinone A significantly induces the contraction of rat detrusor muscles in vitro

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call